Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

JAGX

+ Watchlist+ Portfolio

Jaguar Health, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.38
52-Week Range
$0.33 – $981.75
Market Cap
$4.71M
P/E (TTM)
—
EPS (TTM)
-4012.65
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.01
PEG Ratio
—
Return on Equity
-288.07%
Return on Assets
-36.41%
Gross Margin
81.47%
Operating Margin
-88.20%
Profit Margin
-120.44%
Current Ratio
1.28
Debt/Equity
0.19
Total Debt
$3.52M
Free Cash Flow
$-280.50K
Revenue Growth
-24.00%
Earnings Growth
—
Enterprise Value
$-3.47M

Market Snapshot

About

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing plant-based prescription medicines for gastrointestinal distress. The company markets Mytesi, a prescription medicine for the symptomatic relief of diarrhea in adults living with HIV/AIDS on antiretroviral therapy. Jaguar is also developing Crofelemer for additional indications including cancer therapy-related diarrhea and congenital diarrheal disorders. The company leverages sustainable botanical ingredients from South American rainforests in its drug development efforts.